IL288568A - Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors - Google Patents
Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitorsInfo
- Publication number
- IL288568A IL288568A IL288568A IL28856821A IL288568A IL 288568 A IL288568 A IL 288568A IL 288568 A IL288568 A IL 288568A IL 28856821 A IL28856821 A IL 28856821A IL 288568 A IL288568 A IL 288568A
- Authority
- IL
- Israel
- Prior art keywords
- amino
- methylpyrazin
- decan
- azaspiro
- chloropyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288568A true IL288568A (en) | 2022-02-01 |
Family
ID=71787182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288568A IL288568A (en) | 2019-06-07 | 2021-12-01 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11220501B2 (https=) |
| EP (1) | EP3980128A1 (https=) |
| JP (2) | JP2022534788A (https=) |
| KR (1) | KR20220019017A (https=) |
| CN (2) | CN115141205A (https=) |
| AU (1) | AU2020288631A1 (https=) |
| BR (1) | BR112021022635A2 (https=) |
| CA (1) | CA3142430A1 (https=) |
| IL (1) | IL288568A (https=) |
| MA (1) | MA56113A (https=) |
| MX (1) | MX2021014855A (https=) |
| PH (1) | PH12021552902A1 (https=) |
| SG (1) | SG11202112461QA (https=) |
| TW (1) | TW202112785A (https=) |
| WO (1) | WO2020247643A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CN115141205A (zh) | 2019-06-07 | 2022-10-04 | 锐新医药公司 | Shp2抑制剂的固体形式 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TW200716594A (en) * | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| NZ713361A (en) * | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| MX2020010719A (es) | 2018-04-10 | 2020-11-06 | Revolution Medicines Inc | Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2. |
| CN115141205A (zh) | 2019-06-07 | 2022-10-04 | 锐新医药公司 | Shp2抑制剂的固体形式 |
-
2020
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112461QA (en) | 2021-12-30 |
| US12528807B2 (en) | 2026-01-20 |
| WO2020247643A1 (en) | 2020-12-10 |
| CN114190090A (zh) | 2022-03-15 |
| JP2025138706A (ja) | 2025-09-25 |
| CA3142430A1 (en) | 2020-12-10 |
| US11220501B2 (en) | 2022-01-11 |
| AU2020288631A1 (en) | 2021-12-09 |
| BR112021022635A2 (pt) | 2022-01-04 |
| TW202112785A (zh) | 2021-04-01 |
| CN115141205A (zh) | 2022-10-04 |
| PH12021552902A1 (en) | 2022-04-04 |
| MA56113A (fr) | 2022-04-13 |
| EP3980128A1 (en) | 2022-04-13 |
| JP2022534788A (ja) | 2022-08-03 |
| KR20220019017A (ko) | 2022-02-15 |
| MX2021014855A (es) | 2022-01-18 |
| US20210253574A1 (en) | 2021-08-19 |
| US20220298159A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288568A (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors | |
| CA3294689A1 (en) | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof | |
| IL288236A (en) | 3,2-dihydroquinazoline compounds as inhibitors of nav1.8 | |
| EP3983433A4 (en) | NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT | |
| WO2021022163A3 (en) | Compounds and uses thereof | |
| EP3774166A4 (en) | LASER PROCESSING DEVICE, METHOD OF OPERATION THEREOF AND METHOD OF PROCESSING WORKPIECES USING SAME | |
| WO2018100233A3 (en) | Distributed audio capture and mixing controlling | |
| MX2020002033A (es) | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. | |
| WO2021138046A8 (en) | Strap-segment-cutting system | |
| EP3493206A3 (en) | Electronic apparatus and control method thereof | |
| EP3956341A4 (en) | CD73 INHIBITORS | |
| EP3977757A4 (en) | Audio processing | |
| EP3867324A4 (en) | TWO-PART CYANOACRYLATE/FREE-ADICAL BONDING SYSTEMS | |
| IL320582A (en) | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | |
| EP4046064A4 (en) | SYSTEMS AND METHODS FOR TRACKING GAMING CHIPS | |
| EP4062934A4 (en) | COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES | |
| HK40072890A (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| EP3789449A3 (en) | Polyester having a reduced level of acetaldehyde | |
| MX2021008009A (es) | Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico. | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| EP4079433A4 (en) | POINTED SAW | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| EP4078122A4 (en) | SEMICONDUCTOR METAL-OXIDE FIELD EFFECT TRANSISTOR OVERHEATING DETECTION | |
| HK40073757A (en) | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof | |
| EP4195010A4 (en) | INFORMATION PROCESSING DEVICE THAT MOVES A REGION OF OPERATION |